Modulation of cell growth and apoptosis response in human prostate cancer cells supplemented with tocotrienols

European Journal of Lipid Science and Technology

Volumn 110, Issue 1, 2008, Pages 23-31

  Nesaretnam, Kalanithi ^a   Koon, Teoh Hoon ^a   Selvaduray, Kanga Rani ^a   Bruno, Richard S ^b   Ho, Emily ^b  

^a MALAYSIAN PALM OIL BOARD   (Malaysia)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Fas; Prostate cancer; Tocopherols; Tocotrienols apoptosis

Indexed keywords

EID: 38749114297     PISSN: 14387697     EISSN: 14389312     Source Type: Journal    
DOI: 10.1002/ejlt.200700068     Document Type: Article

References (67)

1. A. Jemal, R. C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, E. Ward, E. J. Feuer, M. J. Thun: Cancer statistics, 2004. CA Cancer J Clin. 2004, 54, 8-29.
2. P. Whelan: Retinoic acid and prostatic cancer cell growth. Prog Clin Biol Res. 1990, 357, 117-120.
3. W. G. Nelson, A. M. De Marzo, W. B. Isaacs: Prostate cancer. N Engl J Med. 2003, 349, 366-381.
4. H. Gronberg: Prostate cancer epidemiology. Lancet 2003, 361, 859-864.
5. W. Isaacs, A. De Marzo, W. G. Nelson: Focus on prostate cancer. Cancer Cell 2002, 2, 113-116.
6. W. Haenzel, M. Kurihara: Studies of Japanese migrants. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst. 1968, 40, 43-68.
7. J. M. Chan, M. J. Stampfer, J. Ma, E. B. Rimm, W. C. Willett, E. L. Giovannucci: Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev. 1999, 8, 893-899.
8. E. A. Klein, I. M. Thompson, S. M. Lippman, P. J. Goodman, D. Albanes, P. R. Taylor, C. Coltman: SELECT: The next prostate cancer prevention trial. Selenium and vitamin E cancer prevention trial. J Urol. 2001, 166, 1311-1315.
9. W. G. Christen, J. M. Gaziano, C. H. Hennekens: Design of physicians' health study II - a randomized trial of beta-carotene, vitamin E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol. 2000, 10, 125-134.
10. S. Hercberg, P. Galan, P. Preziosi, S. Briancon, I. Triol, D. Malvy, A. M. Roussel, A. Favier: Background and rationale behind the SU.VI.MAX study, a prevention trial using nutritional doses of combination of antioxidant vitamins and minerals to reduce cardiovascular diseases and cancers. Supplementation en Vitamines et Mineraux AntioXydants Study. Int J Vitam Nut Res. 1998, 68, 3-20.
11. O. P. Heinonen, J. K. Huttunen, D. Albanes: Alpha-tocopherol, beta-carotene cancer prevention study group (ATBC): The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994, 330, 1029-1035.
12. F. Galli, A. M. Stabile, M. Betti, C. Conte, A. Pistilli, M. Rende, A. Floridi, A. Azzi: The effect of α- and δ-tocopherol and their carboxyethyl hydroxychroman metabolites on prostate cancer cell proliferation. Arch Biochem Biophys. 2004, 423, 97-102.
13. K. Israel, W. Yu, B. G. Sander: Vitamin E succinate induces apoptosis in human prostate cancer cells: Role of Fas in vitamin E succinate-triggered apoptosis. Nutr Cancer 2000, 36, 90-100.
14. K. Nesaretnam, R. Stephen, R. Dils, P. Darbre: Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. Lipids 1998, 33, 461-469.
15. H. Mo, C. E. Elson: Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Proc Soc Exp Biol Med. 2004, 229, 567-585.
16. S. Shah, A. Gapor, P. W. Sylvester: Role of caspasc-8 activation in mediating vitamin E-induced apoptosis in murine mammary cancer cells. Nutr Cancer 2003, 45, 236-246.
17. B. S. McIntyre, K. P. Briski, A. Gapor, P. W. Sylvester: Anti-proliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med. 2000, 224, 292-301.
18. W. Yu, M. Simmons-Menchaca, A. Gapor, B. G. Sander, K. Kline: Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. Nutr Cancer 1999, 33, 26-32.
19. N. Guthrie, A. Gapor, A. F. Chambers, K. K. Carroll: Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen alone and in combination. J Nutr. 1997, 127, 544S-548S.
20. C. Conte, A. Floridi, C. Aisa, M. Piroddi, A. Floridi, F. Galli: γ-Tocotrienol metabolism and anti-proliferative effect in prostate cancer cells. Ann N Y Acad Sci. 2004, 1031, 391-394.
21. H. Stellar: Mechanisms and genes of cellular suicide. Science 1995, 267, 1445-1449.
22. G. I. Evan, K. H. Vousden: Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411, 342-348.
23. P. Farrell, R. Roberts: Vitamin E. Eds. M. Shils, J. A. Olson, M. Shike, Lea & Febiger, Philadelphia, PA (USA) 1994, pp 326-341.
24. K. Nesaretnam, S. Dorasamy, P. Darbre: Tocotrienols inhibit growth of ZR-75-1 human breast cancer cells. Int J Food Science Nutr. 2000, 51, S95-S103.
25. L. He, H. Mo, S. Hadisusilo, A. A. Qureshi, C. E. Elson: Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr. 1997, 127, 668-674.
26. C. E. Elson: Suppression of mevalonate pathway by dietary isoprenoids: Protective roles in cancer and cardiovascular diseases. J Nutr. 1995, 125, 1666S-1672S.
27. C. E. Elson, D. M. Peffley, P. Hentosh, H. Mo: Isoprenoid-mediated inhibition of mevalonate synthesis: Potential application in cancer. Proc Soc Exp Biol Med. 1999, 221, 294-311.
28. B. S. McIntyre, K. P. Briski, M. A. Tirmenstein, M. W. Fariss, A. Gapor, P. W. Sylvester: Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells. Lipids 2000, 35, 171-180.
29. J. V. Tapia-Vieyra, J. Mas-Oliva: Apoptosis and cell death channels in prostate cancer. Arch Med Res. 2001, 32, 175-185.
30. W. E. Mercer: Checking on the cell cycle. J Cell Biochem. 1998, 30/31, 50-54.
31. G. Ray, G. Dhar, P. J. Van Veldhuizen, S. Banerjee, N. K. Saxena, K. Sengupta, S. K. Banerjee: Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways. Biochemistry 2006, 45, 3703-3713.
32. C. Courtemanche, A. C. Huang, I. Elson-Schwab, N. Kerry, B. Y. Ng, B. N. Ames: Folate deficiency and ionizing radiation cause DNA breaks in primary human lymphocytes: A comparison. FASEB J. 2004, 18, 209-211.
33. M. R. Jackman, J. N. Pines: Cyclins and the G2/M transition. Cancer Surv. 1997, 29, 47-73.
34. D. O. Morgan: Principles of CDK regulation. Nature 1995, 374, 131-134.
35. J. Gautier, M. J. Solomon, R. N. Booher, J. F. Bazan, M. W. Kirschner: cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 1991, 67, 197-211.
36. P. Turowski, C. Franckhauser, M. C. Morris, P. Vaglio, A. Fernandez, N. J. Lamb: Functional cdc25C dual-specificity phosphatase is required for S-phase entry in human cells. Mol Biol Cell 2003, 14, 2984-2998.
37. O. W. Rokhlin, G. A. Bishop, B. S. Hostager, T. J. Waldschmidt, S. P. Sidorenko, N. Pavloff, M. C. Kiefer, S. R. Umansky, R. A. Glover, M. B. Cohen: Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res. 1997, 57, 1758-1768.
38. S. R. Downing, P. J. Russell, P. Jackson: Alterations of p53 are common in early stage prostate cancer. Can J Urol. 2003, 10, 1924-1933.
39. C. Abate-Shen, M. M. Shen: Molecular genetics of prostate cancer. Genes Dev. 2000, 14, 2410-2434.
40. S. Huang, C. A. Pettaway, H. Uehara, C. D. Bucana, I. J. Fidler: Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogens 2001, 20, 4188-4197.
41. K. Reiss, J. Y. Wang, G. Romano, F. B. Furnari, W. K. Cavenee, A. Morrione, X. Tu, R. Baserga: IGF-T receptor signaling in a prostatic cancer cell with a PTEN mutation. Oncogene 2000, 19, 2687-2694.
42. S. Nagata: Apoptosis mediated by the Fas system. Prog Mol Subcell Biol. 1996, 16, 87-103.
43. N. Kayagaki, A. Kawasaki, T. Ebata, H. Ohmoto, S. Ikeda, S. Inoue, K. Yoshino, K. Okumura, H. Yagita: Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995, 182, 1777-1783.
44. S. M. Mariani, B. Matiba, C. Baumler, P. H. Krammer: Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol. 1995, 25, 2303-2307.
45. M. J. Martinez-Lorenzo, A. Anel, S. Gamen, N. I. Monle, P. Lasierra, L. Larrad, A. Pineiro, M. A. Alava, J. Naval: Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J Immunol. 1999, 163, 1274-1281.
46. T. Suda, T. Okazaki, Y. Naito, T. Yokota, N. Arai, S. Ozaki, K. Nakao, S. Nagata: Expression of Fas ligand in cells of T cell lineage. J Immunol. 1995, 154, 3806-3813.
47. Y. Sasaki, H. Ahmed, T. Takeuchi, N. Moriyama, K. Kawabe: Immunohistochemical study of Fas, Fas ligand and interleukin-1 beta converting enzyme expression in human prostatic cancer. Br J Urol. 1998, 81, 852-855.
48. Q. Y. Liu, M. A. Rubin, C. Omene, S. Lederman, C. A. Stein: Fas ligand is constitutively secreted by prostate cancer cells in vitro. Clin Cancer Res. 1998, 4, 1803-1811.
49. L. Xerri, E. Devilard, J. Hassoun, C. Mawas, F. Birg: Fas ligand is not only expressed in iimmune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol. 1997, 50, 87-91.
50. H. R. Salih, G. C. Starling, M. Knauff, M. J. Llewellyn, P. M. Davis, W. J. Pitts, A. Aruffo, P. A. Kiener: Retinoic acid and vitamin E modulate expression and release of CD 178 in carcinoma cells: Consequences for induction of apoptosis in CD-95 sensitive cells. Exp Cell Res. 2001, 270, 248-258.
51. A. Suzuki, A. Matsuwaza, T. Iguchi: Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract. Oncogene 1996, 13, 31-37.
52. T. Takeuchi, Y. Sasaki, T. Ueki, T. Kaziwara, N. Moriyama: Modulation of growth and apoptosis response in PC3 and LNCaP prostate-cancer cell lines by Fas. Int J Cancer 1996, 67, 709-714.
53. L. B. Owen-Schaub, R. Radinsky, E. Kruzel, K. Berry, S. Yonehara: Anti-Fas on nonhematopoietic tumours: Levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 1994, 54, 1580-1586.
54. M. Hahne, D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini, J. Tschopp: Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumour immune escape. Science 1996, 274, 1363-1366.
55. H. Rabinowich, T. E. Reichert, Y. Kashii, B. R. Gastman, M. C. Bell, T. L. Whiteside: Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumour-associated lymphocytes. J Clin Invest. 1998, 101, 2579-2588.
56. S. Strand, W. J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer, P. R. Galle: Lymphocyte apoptosis induced by CD95 (APO1-Fas) ligand-expressing tumour cells - A mechanism of immune evasion? Nat Med. 1996, 2, 1361-1366.
57. J. O'Connell, M. W. Bennett, G. C. O'Sullivan, J. K. Collins, F. Shanahan: The Fas counterattack: A molecular mechanism of tumor immune privilege. Mol Med. 1997, 3, 297-300.
58. T. H. Holmstrom, S. C. Chow, I. Elo, E. T. Coffey, S. Orrenius: Suppression of Fas/APO-1-mediated apoptosis by mitogen-activated kinase signaling. J Immunol. 1998, 160, 2626-2636.
59. H. Ungefroren, M. Voss, M. Jansen, C. Roeder, D. Henne-Burns: Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res. 1998, 58, 1741-1749.
60. T. S. Griffith, T. Brunner, S. M. Fletcher, D. R. Green, T. A. Ferguson: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995, 270, 1189-1192.
61. D. Bellgrau, D. Gold, H. Selawry, J. Moore, A. Franzusoff, R. C. Duke: A role for the CD95 ligand in preventing graft rejection. Nature 1995, 377, 630-632.
62. T. S. Griffith, X. Yu, J. M. Herndon, D. R. Green, T. A. Ferguson: CD-95-induced apoptosis of lymphocytes in an immune privilege site induces immunological tolerance. Immunity 1996, 5, 7-16.
63. S. Ray, A. Almasan: Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res. 2003, 63, 4713-4723.
64. R. W. Watson, R. Coffey, A. O'Neill, J. M. Fitzpatrick: Caspase protease manipulation: A novel approach to apoptotic induction in prostate cancer. Prostate Cancer Prostatic Dis. 1999, 2, 534-856.
65. J. Kumi-Diaka, N. A. Sanderson, A. Hall: The mediating role of caspase-3 protease in the intracellular mechanism of genistein-induced apoptosis in human prostatic carcinoma cell lines, DU145 and LNCaP. Biol Cell 2000, 92, 595-604.
66. C. Bowen, H. J. Voeller, K. Kikly, E. P. Gelmann: Synthesis of procaspases-3 and -7 during apoptosis in prostate cancer cells. Cell Death Differ. 1999, 6, 394-401.
67. M. Marcelli, G. R. Cunningham, M. Walkup, Z. He, L. Sturgis, C. Kagan, R. Mannucci, I. Nicoletti, B. Teng, L. Denner: Signalling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res. 1999, 59, 382-390.